New FDA Guidance Clinical Trial Considerations To Support Ac

On April 6, 2023, AbbVie announced that it was voluntarily withdrawing ibrutinib, which was granted accelerated approval for two indications: mantle...

Related Keywords

Marjoriee Zettler , , Drug Administration , Oncologic Drugs Advisory Committee , Regor Pharmaceuticals Inc , Drug Administration Expedited Development , Us Government Accountability Office , Oncology Center , Drug Administration Accelerated Approval Of Malignant Hematology , Regor Pharmaceuticals , Project Confirm , Reduce Risk , Require Stronger Evidence Of Safety And , Drug Omnibus Reform Act , Consolidated Appropriations Act , Mantle Cell Lymphoma , Marginal Zone Lymphoma , Participants With , Refractory Mantle Cell Lymphoma , Tyrosine Kinase Inhibitor , Subjects With , Refractory Marginal Zone , Tyrosine Kinase Inhibitor Ibrutinib Given , Combination With Bendamustine , Patients With Newly Diagnosed Mantle Cell , Untreated Mantle Cell , Combination With Either Bendamustine , Expedited Programs , Serious Conditions , Preview Programs , Nonorphan Novel Drugs Approved From , Bend Points , Patient Reported Outcomes , Novel Oncology Drugs Approved Between , Year Experience , Drug Administration Accelerated Approval , Malignant Hematology , Oncology Drugs , Many Applications , Postapproval Oversight Need Improvement , Appropriations Act , Clinical Trial Considerations , Support Accelerated Approval , Clinical Oncology ,